Immunoturbidimetric assay for quantification of vWF:Ag



  • Ready-to-use liquid reagent technology
  • Excellent linearity with extended dynamic range up to 600% for high vWF concentrations (inflammation, liver diseases, prognosis)
  • High sensitivity for low vWF concentrations (VWD)
  • Neutralising agents for Rheumatoid factor included
  • Automation protocols available for most common coagulation analysers


LIAPHEN™ vWF:Ag is an immunoturbidimetric method, based on antigen-antibody reaction: vWF antigen of the sample reacts with Latex particles sensitized with rabbit anti-vWF polyclonal antibodies, leading to latex particles agglutination. This agglutination can be directly detected by a change of absorbance. The absorbance change is directly proportional to the amount of vWF:Ag in the sample.


Ordering information

Product Name Reference Package
LIAPHENTM vWF:Ag (CE-IVD) 120206  R1: 4 x 5 ml

R2: 4 x 6 ml

BIOPHENTM  Plasma Calibrator (CE-IVD) 222101 12 x 1 ml
BIOPHENTM  Normal Controle Plasma (CE-IVD) 223201 12 x 1 ml
BIOPHENTM  Abnormal Controle Plasma (CE-IVD) 223301 12 x 1 ml


Other related products

Product Name Assay principle Reference Package
ZYMUTESTTM vWF     (CE-IVD) An Elisa assay for measuring human vWF in plasma, or in any fluid where vWF can be present. RK030A 96 tests
ZYMUTESTTM vWF:CBA (CE-IVD) A bio-immuno Elisa assay for measuring human vWF Collagen Binding Activity (CBA) in plasma, or in any fluid where vWF:CBA van be present RK038A 96 tests
 BIOPHENTM  FVIII:C  (CE-IVD)  A chromogenic assay for measuring the factor VIII:C activity in human plasma or in factor VIII:C concentrates, using a chromogenic method, manual or automated. 221402


2 x 2,5 ml

2 x 6 ml

 FVIII:C Deficient Plasma (CE-IVD)  A clotting assay for the measurement of Factor VIII:C activity in human citrated plasma, to be used in the presence of cephalin, activator and calcium (aPTT reagent).  DP040A


1 x 1 ml

6 x 1 ml



  1.  Luo et al. von Willebrand Factor: more than a regulator of hemostasis and thrombosis. Acta Haematol, 2012, 128:158-169.
  2. Peyvandi et al. Role of von Willebrand Factor in the haemostasis. Blood Transfus, 2011, 9 suppl 2:s3-s8.
  3. Sadler JE(1), Budde UEikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, et al. Update on the pathopphysiology and the classification of von Willebrand disease: a report of the Subcommitte on von Willebrand Factor. J Thromp Haemost 2006 Oct;4(10):2103-2114
  4. favaloro EJ. new developments in the diagnosis and treatment of von Willebrand disease. Clin. Invest. 2012 2(8), 781-795